Shanghai InnoStar Bio-tech Co

Shanghai InnoStar Bio-tech Co EV/EBITDA

The EV/EBITDA (Enterprise Value to EBITDA) of Shanghai InnoStar Bio-tech Co (688710.SS) as of Oct 21, 2026 is 266.83. In the previous year, EV/EBITDA (Enterprise Value to EBITDA) was 29.50 — a change of 804.37% (higher).

EV/EBITDA

266.83

YoY

804.37%

Last updated:

EV/EBITDA (Enterprise Value to EBITDA) of Shanghai InnoStar Bio-tech Co is 2025 266.83 . EV/EBITDA (Enterprise Value to EBITDA) of Shanghai InnoStar Bio-tech Co was 2024 29.50 . It decreases by 804.37% higher compared to the previous year.

The Shanghai InnoStar Bio-tech Co EV/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/EBITDA
Date
EV/EBITDA
Jan 1, 2021
56.00 CNY
Jan 1, 2022
34.84 CNY
Jan 1, 2023
24.69 CNY
Jan 1, 2024
29.50 CNY
Jan 1, 2025
266.83 CNY
The Shanghai InnoStar Bio-tech Co EV/EBITDA history
YEAREV/EBITDAYoY
266.83+804.37%
29.50+19.51%
24.69-29.14%
34.84-37.79%
56.00—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Shanghai InnoStar Bio-tech Co Stock analysis

What does Shanghai InnoStar Bio-tech Co do? Shanghai InnoStar Bio-tech Co Ltd generates revenue through biopharmaceutical non-clinical research services, primarily targeting pharmaceutical companies and biotech firms. The company offers early drug development evaluation services that develop multiple early toxicity rapid prediction and screening models. Non-clinical research services include non-clinical safety evaluation, non-clinical pharmacokinetic research, and non-clinical pharmacodynamic research. Clinical testing and translational research provides analytical methods and data support for clinical pharmacokinetics, efficacy, and safety research of innovative drug projects. The firm's clients are pharmaceutical companies and biotech firms seeking to advance innovative drug projects through non-clinical and clinical research. These clients purchase the company's services to support early drug development, safety evaluation, and translational research needs. The company's focus on biopharmaceutical non-clinical research positions it to serve the growing demand for specialized research services in the life sciences sector. Shanghai InnoStar Bio-tech Co Ltd's service portfolio is structured around three core areas: early drug development evaluation, non-clinical research, and clinical testing and translational research. Each segment provides specialized services that support different stages of drug development, from initial toxicity screening to clinical research support. The company's revenue is derived from these specialized service offerings delivered to pharmaceutical and biotech clients. Shanghai InnoStar Bio-tech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Shanghai InnoStar Bio-tech Co stock

EV/EBITDA (Enterprise Value to EBITDA) of Shanghai InnoStar Bio-tech Co is 266.83 in 2025.

EV/EBITDA (Enterprise Value to EBITDA) of Shanghai InnoStar Bio-tech Co changed from 29.50 to 266.83, representing a 804.37% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/EBITDA (Enterprise Value to EBITDA) Shanghai InnoStar Bio-tech Co since 2006 – with annual values, charts, and detailed analysis.

The EV/EBITDA ratio is a widely used valuation metric that compares a company's enterprise value to its EBITDA. It normalizes for differences in capital structure, taxation, and depreciation policies.

To evaluate EV/EBITDA (Enterprise Value to EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBITDA (Enterprise Value to EBITDA).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBITDA (Enterprise Value to EBITDA)'s Shanghai InnoStar Bio-tech Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Shanghai InnoStar Bio-tech Co

All Key Metrics — Shanghai InnoStar Bio-tech Co